Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers
暂无分享,去创建一个
Elena Pereira | Robert Sebra | Navya Nair | E. Schadt | R. Sebra | Rong Chen | P. Dottino | J. Martignetti | A. Uzilov | E. Moshier | E. Pereira | Rong Chen | John A. Martignetti | Peter Dottino | Eric Schadt | Olga Camacho-Vanegas | Erin Moshier | O. Camacho-Vanegas | Andrew Uzilov | Melissa Wooten | Monica Prasad-Hayes | Sanya Anand | Sandra Catalina Camacho | Leopold Garnar-Wortzel | Konstantin Zakashansky | Ann Marie Beddoe | K. Zakashansky | A. Beddoe | S. Anand | M. Prasad-Hayes | N. Nair | Melissa Wooten | Sandra Catalina Camacho | Leopold Garnar-Wortzel | O. Camacho‐Vanegas
[1] N. Rosenfeld,et al. Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA , 2012, Science Translational Medicine.
[2] G. Rustin,et al. Role of tumour markers in monitoring epithelial ovarian cancer , 2000, British Journal of Cancer.
[3] Jorge S. Reis-Filho,et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer , 2015, Science Translational Medicine.
[4] J. Gohagan,et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. , 2011, JAMA.
[5] Bert Vogelstein,et al. DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES , 2014 .
[6] Carlos Caldas,et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.
[7] H. Shah,et al. Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA. , 2014, Neoplasia.
[8] R. Manfredi,et al. Which imaging technique should we use in the follow up of gynaecological cancer? , 2014, Best practice & research. Clinical obstetrics & gynaecology.
[9] Kendra Johnson,et al. Integration of and adherence to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines) in a Community Cancer Center , 2015 .
[10] G. Ricolleau,et al. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] H. Nielsen,et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery , 2015, Gut.
[12] R. Bast. CA 125 and the detection of recurrent ovarian cancer , 2010, Cancer.
[13] Rochelle L. Garcia,et al. Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. , 2005, American journal of obstetrics and gynecology.
[14] Lori J Sokoll,et al. Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. , 2003, Journal of the National Cancer Institute.
[15] Y. Doki,et al. Monitoring gastric cancer progression with circulating tumour DNA , 2014, British Journal of Cancer.
[16] P. Disaia,et al. Clinical Gynecologic Oncology , 1981 .
[17] R. Mannel,et al. The Adnexal Mass , 2012 .
[18] A. Sood,et al. Quantification of Total Plasma Cell‐Free DNA in Ovarian Cancer Using Real‐Time PCR , 2006, Annals of the New York Academy of Sciences.
[19] A. Nicholson,et al. Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies. , 2015, Clinical chemistry.
[20] R. Kryscio,et al. Preoperative differentiation of malignant from benign ovarian tumors: the efficacy of morphology indexing and Doppler flow sonography. , 2003, Gynecologic oncology.
[21] D. Brizel,et al. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .